NASDAQ: PRTC - PureTech Health plc

半年間の収益性: -14.52%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール PureTech Health plc

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について PureTech Health plc

PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies.

さらに詳しく
It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

IPO date 2020-11-16
ISIN US7462371060
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.puretechhealth.com
Цена ао 16.75
1日あたりの価格変動: -0.4407% (17.7)
週ごとの価格変動: +5.47% (16.7088)
月ごとの料金変更: -6.71% (18.89)
3ヶ月間の価格変動: -9.68% (19.51)
半年間の価格変動: -14.52% (20.615)
年間の価格変動: -38.17% (28.5)
3年間の価格推移: -38.77% (28.78)
年初からの価格変動: -10.37% (19.66)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 211.58 1
P/BV 1.24 9
P/E 0 0
EV/EBITDA -3.8 0
合計: 3.63

効率

名前 意味 学年
ROA, % -9.47 0
ROE, % -14.16 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0.0657

義務

名前 意味 学年
Debt/EBITDA -0.1806 10
合計: 9.6

成長の衝動

名前 意味 学年
収益性 Revenue, % -61.72 0
収益性 Ebitda, % -87.75 0
収益性 EPS, % -101.65 0
合計: 0
さらに詳しく

機関 音量 共有, %
Pentwater Capital Management LP 10244 0.04
Tower Research Capital LLC (TRC) 43 0
UBS Group AG 20 0

ETF共有, %年間の利益率, %配当金, %
Amplify BlueStar Israel Technology ETF 0.30643 20.42 0.47569
Invesco Global Listed Private Equity ETF 0.29338 29.43 3.4983
Dimensional International Small Cap ETF 0.02653 5.69 3.34747
SPDR S&P International Small Cap ETF 0.0233 8.94 3.10348
Schwab International Small-Cap Equity ETF 0.0133 10.07 3.20638
SPDR Portfolio Europe ETF 0.00347 8.94 3.66537
Dimensional International Core Equity 2 ETF 0.00136 6.52 3.69996
Avantis International Equity ETF 0.00099 6.46 3.80856
Dimensional International Core Equity Market ETF 0.00032 13.09 3.48343
Vanguard FTSE All-World ex-US Small-Cap ETF 0 9.39 3.09932
Vanguard ESG International Stock ETF 0 6.39 3.07501
0.0611.393.13



スーパーバイザー 役職 支払い 生年
Ms. Daphne Zohar Founder, Senior Advisor & Board Observer 3.99M 1971 (54 年)
Dr. Bharatt M. Chowrira J.D., Ph.D. CEO & Executive Director 2.19M 1965 (60 年)
Dr. David R. Elmaleh Ph.D. Co-Founder & Senior Advisor N/A 1948 (77 年)
Ms. Allison Mead Talbot Head of Communications & Investor Relations N/A
Mr. Spencer Ball Senior Vice President of Human Resources N/A
Dr. Eric Elenko Ph.D. Co-Founder & President N/A 1973 (52 年)
Mr. Eric Green M.B.A. Chief Operating Officer N/A
Mr. Charles Sherwood III, J.D., Ph.D. General Counsel & Company Secretary N/A
Dr. Robert S. Langer Jr., Ph.D., ScD Co-Founder & Non-Executive Director 1949 (76 年)
Mr. Michael Inbar CPA, M.B.A. Senior Vice President of Finance

住所: United States, Boston. MA, 6 Tide Street - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.puretechhealth.com